{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:43:58Z","timestamp":1778917438212,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21-CA191594"],"award-info":[{"award-number":["R21-CA191594"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00520-021-06408-1","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T01:02:26Z","timestamp":1625619746000},"page":"87-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Correlates of fatigue severity in patients with chronic myeloid leukemia treated with targeted therapy"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6281-2512","authenticated-orcid":false,"given":"Laura B.","family":"Oswald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly A.","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah L.","family":"Eisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aasha I.","family":"Hoogland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Knoop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley M.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendra","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul B.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather S. L.","family":"Jim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"issue":"9","key":"6408_CR1","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","volume":"119","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, O\u2019Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J et al (2012) Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981\u20131987","journal-title":"Blood"},{"issue":"2","key":"6408_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11899-016-0306-5","volume":"11","author":"KE Flynn","year":"2016","unstructured":"Flynn KE, Atallah E (2016) Quality of life and long-term therapy in patients with chronic myeloid leukemia. Curr Hematol Malig Rep 11(2):80\u201385","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"6408_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.6004\/jnccn.2018.7098","volume":"17","author":"JM Jacobs","year":"2019","unstructured":"Jacobs JM, Ream ME, Pensak N, Nisotel LE, Fishbein JN, MacDonald JJ et al (2019) Patient experiences with oral chemotherapy: adherence, symptoms, and quality of life. J Natl Compr Canc Netw 17(3):221\u2013228","journal-title":"J Natl Compr Canc Netw"},{"issue":"17","key":"6408_CR4","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F et al (2011) Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118(17):4554\u20134560","journal-title":"Blood"},{"issue":"6","key":"6408_CR5","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/bjc.2012.348","volume":"107","author":"F Efficace","year":"2012","unstructured":"Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M et al (2012) Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer 107(6):904\u2013909","journal-title":"Br J Cancer"},{"issue":"5","key":"6408_CR6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1182\/blood-2013-01-477687","volume":"122","author":"LA Williams","year":"2013","unstructured":"Williams LA, Garcia Gonzalez AG, Ault P, Mendoza TR, Sailors ML, Williams JL et al (2013) Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 122(5):641\u2013647","journal-title":"Blood"},{"issue":"4","key":"6408_CR7","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00520-012-1630-5","volume":"21","author":"KM Phillips","year":"2013","unstructured":"Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ et al (2013) Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer 21(4):1097\u20131103","journal-title":"Support Care Cancer"},{"key":"6408_CR8","doi-asserted-by":"crossref","unstructured":"Janssen L, Blijlevens NMA, Drissen MMCM, Bakker EA, Nuijten MAH, Janssen JJWM et al (2021) Fatigue in chronic myeloid leukemia patients\u00a0on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity. Haematologica\u00a0106(7):1876\u20131882","DOI":"10.3324\/haematol.2020.247767"},{"issue":"7","key":"6408_CR9","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/leu.2013.51","volume":"27","author":"F Efficace","year":"2013","unstructured":"Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL et al (2013) Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 27(7):1511\u20131519","journal-title":"Leukemia"},{"issue":"10","key":"6408_CR10","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1002\/cncr.31323","volume":"124","author":"F Efficace","year":"2018","unstructured":"Efficace F, Castagnetti F, Martino B, Breccia M, D\u2019Adda M, Angelucci E et al (2018) Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. Cancer 124(10):2228\u20132237","journal-title":"Cancer"},{"issue":"4","key":"6408_CR11","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3324\/haematol.2013.093724","volume":"99","author":"F Efficace","year":"2014","unstructured":"Efficace F, Rosti G, Aaronson N, Cottone F, Angelucci E, Molica S et al (2014) Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica 99(4):788\u2013793","journal-title":"Haematologica"},{"issue":"4","key":"6408_CR12","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00520-016-3520-8","volume":"25","author":"AR Peoples","year":"2017","unstructured":"Peoples AR, Roscoe JA, Block RC, Heckler CE, Ryan JL, Mustian KM et al (2017) Nausea and disturbed sleep as predictors of cancer-related fatigue in breast cancer patients: a multicenter NCORP study. Support Care Cancer 25(4):1271\u20131278","journal-title":"Support Care Cancer"},{"issue":"3","key":"6408_CR13","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/pon.4605","volume":"27","author":"LA Bevilacqua","year":"2018","unstructured":"Bevilacqua LA, Dulak D, Schofield E, Starr TD, Nelson CJ, Roth AJ et al (2018) Prevalence and predictors of depression, pain, and fatigue in older- versus younger-adult cancer survivors. Psychooncology 27(3):900\u2013907","journal-title":"Psychooncology"},{"issue":"1","key":"6408_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11764-017-0641-0","volume":"12","author":"MSY Thong","year":"2018","unstructured":"Thong MSY, Mols F, van de Poll-Franse LV, Sprangers MAG, van der Rijt CCD, Barsevick AM et al (2018) Identifying the subtypes of cancer-related fatigue: results from the population-based PROFILES registry. J Cancer Surviv 12(1):38\u201346","journal-title":"J Cancer Surviv"},{"issue":"10","key":"6408_CR15","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1007\/s00520-016-3241-z","volume":"24","author":"AM Nelson","year":"2016","unstructured":"Nelson AM, Gonzalez BD, Jim HS, Cessna JM, Sutton SK, Small BJ et al (2016) Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Support Care Cancer 24(10):4159\u20134166","journal-title":"Support Care Cancer"},{"issue":"4","key":"6408_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/00002820-200208000-00004","volume":"25","author":"N de Jong","year":"2002","unstructured":"de Jong N, Courtens AM, Abu-Saad HH, Schouten HC (2002) Fatigue in patients with breast cancer receiving adjuvant chemotherapy: a review of the literature. Cancer Nurs 25(4):283\u201397 (quiz 98-9)","journal-title":"Cancer Nurs"},{"issue":"1","key":"6408_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/cncr.32521","volume":"126","author":"HSL Jim","year":"2020","unstructured":"Jim HSL, Hyland KA, Nelson AM, Pinilla-Ibarz J, Sweet K, Gielissen M et al (2020) Internet-assisted cognitive behavioral intervention for targeted therapy-related fatigue in chronic myeloid leukemia: results from a pilot randomized trial. Cancer 126(1):174\u2013180","journal-title":"Cancer"},{"key":"6408_CR18","unstructured":"Center for Disease Control and Prevention. About Adult BMI 2020 [Available from:\u00a0https:\/\/www.cdc.gov\/healthyweight\/assessing\/bmi\/adult_bmi\/index.html.\u00a0Accessed 3 Aug 2020"},{"issue":"3 Suppl 2","key":"6408_CR19","first-page":"13","volume":"34","author":"D Cella","year":"1997","unstructured":"Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34(3 Suppl 2):13\u201319","journal-title":"Semin Hematol"},{"key":"6408_CR20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123056","volume-title":"Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) in patients with chronic lymphocytic leukemia (CLL)","author":"D Eek","year":"2019","unstructured":"Eek D, Ivanescu C, Kool-Houweling L, Cella D (2019) Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) in patients with chronic lymphocytic leukemia (CLL). American Society of Hematology, Washington DC"},{"issue":"3","key":"6408_CR21","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570\u2013579","journal-title":"J Clin Oncol"},{"issue":"9","key":"6408_CR22","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s11136-008-9398-2","volume":"17","author":"D Victorson","year":"2008","unstructured":"Victorson D, Barocas J, Song J, Cella D (2008) Reliability across studies from the functional assessment of cancer therapy-general (FACT-G) and its subscales: a reliability generalization. Qual Life Res 17(9):1137\u20131146","journal-title":"Qual Life Res"},{"issue":"1","key":"6408_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pain.2010.09.001","volume":"152","author":"JW Ditre","year":"2011","unstructured":"Ditre JW, Gonzalez BD, Simmons VN, Faul LA, Brandon TH, Jacobsen PB (2011) Associations between pain and current smoking status among cancer patients. Pain 152(1):60\u201365","journal-title":"Pain"},{"issue":"1","key":"6408_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/00005650-197601000-00006","volume":"14","author":"M Bergner","year":"1976","unstructured":"Bergner M, Bobbitt RA, Pollard WE, Martin DP, Gilson BS (1976) The sickness impact profile: validation of a health status measure. Med Care 14(1):57\u201367","journal-title":"Med Care"},{"issue":"8","key":"6408_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/00005650-198108000-00001","volume":"19","author":"M Bergner","year":"1981","unstructured":"Bergner M, Bobbitt RA, Carter WB, Gilson BS (1981) The sickness impact profile: development and final revision of a health status measure. Med Care 19(8):787\u2013805","journal-title":"Med Care"},{"issue":"8","key":"6408_CR26","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1249\/01.MSS.0000078924.61453.FB","volume":"35","author":"CL Craig","year":"2003","unstructured":"Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE et al (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35(8):1381\u20131395","journal-title":"Med Sci Sports Exerc"},{"key":"6408_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/1479-5868-8-115","volume":"8","author":"PH Lee","year":"2011","unstructured":"Lee PH, Macfarlane DJ, Lam TH, Stewart SM (2011) Validity of the International Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act 8:115","journal-title":"Int J Behav Nutr Phys Act"},{"key":"6408_CR28","unstructured":"Forde C. Scoring the International Physical Activity Questionnaire (IPAQ): Trinity College Dublin; [Available from:\u00a0https:\/\/ugc.futurelearn.com\/uploads\/files\/bc\/c5\/bcc53b14-ec1e-4d90-88e3-1568682f32ae\/IPAQ_PDF.pdf.\u00a0Accessed 3 Aug 2020"},{"key":"6408_CR29","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics [Internet]: Surveillance Research Program, National Cancer Institute; [Available from:\u00a0https:\/\/seer.cancer.gov\/explorer\/.\u00a0Accessed 3 Aug 2020"},{"issue":"2","key":"6408_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13(2):63\u201374","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"6408_CR31","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0885-3924(02)00529-8","volume":"24","author":"D Cella","year":"2002","unstructured":"Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24(6):547\u2013561","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"6408_CR32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/0163278705275341","volume":"28","author":"PS Brucker","year":"2005","unstructured":"Brucker PS, Yost K, Cashy J, Webster K, Cella D (2005) General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof 28(2):192\u2013211","journal-title":"Eval Health Prof"},{"key":"6408_CR33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-1-79","volume":"1","author":"K Webster","year":"2003","unstructured":"Webster K, Cella D, Yost K (2003) The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1:79","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"6408_CR34","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/0163278705275340","volume":"28","author":"KJ Yost","year":"2005","unstructured":"Yost KJ, Eton DT (2005) Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof 28(2):172\u2013191","journal-title":"Eval Health Prof"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06408-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06408-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06408-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T07:09:17Z","timestamp":1638342557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06408-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,7]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["6408"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06408-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,7]]},"assertion":[{"value":"29 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Chesapeake Institutional Review Board (Pro00023476).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent to participate was obtained from all individual participants included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants consented to having de-identified and aggregate study data published.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Dr. Jim is a paid consultant for RedHill BioPharma, Janssen Scientific Affairs, and Merck. The other authors have no relevant conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}